Home / Resource Library / Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphomas: A systematic review and proportionality meta-analysis
Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphomas: A systematic review and proportionality meta-analysis